Identification of compounds from *Aframomum melengueta* (alligator pepper) as potential inhibitors of the Sex Hormone Binding Globulin (SHBG) in male infertility

C. B. Adindu¹* and P. I. Okeke²

 *¹Department of Chemistry, Imo State University, P M B 2000 Owerri, Imo State Nigeria.
Phone +2347030676855 E-mail: <u>blessingojiegbe@yahoo.com</u>, blessingadindu@imsu.edu.ng
² Department of Basic Science, Alvan Ikoku University of Education Owerri.

ABSTRACT

Human sex hormone binding globulin (SHBG) is a glycoprotein produced and secreted by the liver and is capable of binding androgens and estrogens in males. Both androgens and estrogens are important hormones that help in the development of sexual and reproductive tissues. The present work investigates the active chemical components of Aframomum melegueta (Alligator pepper) as well as study their involvement as potential drug lead to inhibiting Sex hormone binding globulin (SHBG) receptor protein that is involved in the various cases of male infertility. Phytochemical identification of the constituents was achieved by Fourier transform infrared spectroscopy (FTIR) and gas chromatography-mass spectrophotometry GC-MS experiments, while the ligand-target interaction to discover the drug lead candidates was achieved by molecular docking. Adsorption, distribution, metabolism, excretion, and toxicity (ADMET) screening was performed to ascertain the suitability of the compounds as drug lead candidates. The GC-MS result revealed a total of 30 compounds, the molecular docking results showed that 5-Hydroxy-1-(4-hydroxy-3methoxyphenyl)decan-3-one which was found to be present in 43.2511%, gave a binding energy of -7.0 Kcal mol⁻ which is an indication that it might form a good drug lead candidate for the inhibition of the Sex hormone binding globulin. The ADMET study showed that all the compounds above 1% from the GC-MS study proved leading drug candidates with great efficacy, no toxicity, no cardiotoxicity and no carcinogenicity was observed.

Keywords: Aframomum melegueta, Sex hormone binding globulin, male infertility, Androgen,

estrogen

INTRODUCTION

Infertility is a reproductive disorder that affects many families especially in Africa ¹⁻³.

Male infertility affects at least one in every six couples and interferes with the process of

spermatogenesis ⁴. It also reduces sperm quality as well as quantity. Male infertility occurs concurrently with diabetes mellitus, cardiovascular disorder, high blood pressure, chronic liver disease and vitamins deficiency ⁵⁻⁸. Drug misuse, excessive stress, environmental hazards are also reported in many cases of male infertility ⁹⁻¹⁰.

Androgen is a sex steroid hormone that regulates the development and maintenance of male sex characteristics ¹¹⁻¹².it plays a significant role in maintaining normal spermatogenesis (the process of sperm cells production) in man. If the amount of androgen reduces in man it could result in male infertility. A special form of estrogen hormone called estradiol is very crucial in sperm production and male sexuality ¹³⁻¹⁴. High estrogen level can cause slow sperm production and makes it difficult for the individual to create healthy sperm. Human Sex hormone binding globulin (SHBG) is the high molecular weight plasma protein produced by the liver and controls the quantity of testosterone that the body tissue can use ¹⁵⁻¹⁶, it binds androgens and estrogens and plays an important role in maintaining the balance between unbound and bound sex steroids. little SHBG in the body can cause problem to the individual. Obesity, liver

problem, hyperthyroidism and age can affect the level of SHBG in the body. The genetic mutations in the genes of the SHBG, specifically mutated rs6259 and rs727428 loci, can lead to infertility in men ¹⁷.

Many phytochemicals with medicinal applications have been discovered in medicinal plants. Interestingly, traditional medicines have proven to show fewer side effects as well as attacking several targets ¹⁸⁻²⁰.

Aframomum melegueta (Alligator pepper) is a spice that belongs to *the* Zingiberaceae family ²¹⁻²². Seeds of *Aframomum melegueta* are used as spice in African dishes due to its sweet-smelling aroma ²³. Is also serves as a material of ethnomedical preparations used for the treatment of stomach ache, diarrhea, and in some cases snack bite ²⁴⁻²⁵. The present work investigates the active components of *Aframomum melegueta* as well as their Sex Hormone Binding Globulin (SHBG) inhibiting potential in male infertility.

MATERIALS AND METHODS

Preparation of plant material

The *Aframomum melegueta* (Alligator pepper) used for this study was obtained from a local market in Owerri Imo State Nigeria and ground into powdered form. It was then

dipped in chloroform and left for 72 hours ²⁶⁻ ²⁷ and filtered. The filtrate was evaporated and sent for FTIR and GC-MS studies.

Preparation of Ligands

GC-MS analysis was used to identify 30 compounds from the *Aframomum melengueta* powder. The 3-Dimensional (3D) conformers (SDF files) of the active ingredients were downloaded from the pubchem online data base ²⁸ and used as the ligand for the molecular docking analysis,

Preparation of protein target

The three-dimensional structure of the sex hormone-binding globulin (SHBG) receptor with PDB ID: 1KDM was identified from literature ²⁹ and downloaded from Protein Data Bank (PDB) and formed the target for the docking process. Target preparation was done in discovery studio online software where the interfering crystallographic water particles and the co-crystalized ligand were removed. The amino acids found in the active site of the target are Asp 50, Lys 134, Ala 160, Glu 52, Asp 85, Asn 82, Leu 171, Thr 40, Ser 41, Asp 65




Figure 1 The sex hormone-binding globulin protein target with the active site amino acids

Drug Screening

The suitability of the identified compounds as drug candidates was performed using admetsar online software. Their canonical smiles were retrieved from pubchem software and submitted to admesar for ADMET (absorption, distribution. metabolism, excretion, and toxicity) predictive results. The reason for this screening is to identify the drug like candidate suitable to be recommended as acceptable drug candidate which do not violate more than one of Lipinski's rule of five $(Ro5)^{30-31}$, which states that a compound which is to be accepted as drug should have a molecular mass of < 500 Dalton, the hydrogen bond acceptor should be not be more than 10, the hydrogen bond donor should not exceed 5, molar refractive index should be between 40-130, and that the partition coefficient (LogP) should be less than 5.

Molecular docking study

Molecular docking simulation was done between the 30 plant-derived phytochemical and the previously prepared sex hormonebinding globulin protein target using PYRX software. The protein target was used as the macromolecule and the ligands were minimized in PYRX and set as Autodock ligand pdbqt. The docked conformations with the lowest docking energies were ascribed as the best ones ³²⁻³³. The post post-docking visualization of the interaction between the protein target and the ligands was performed in discovery studio.

RESULTS

Phytochemical Results

Fourier transform infrared spectroscopy (FTIR) and gas chromatography-mass spectroscopy experiments were performed on the Aframomum melegueta powder to identify the phytochemicals therein. The FTIR result showed the functional groups in Table 1 while the GC-MS analysis revealed 30 compounds with medicinal and therapeutic properties ³⁴. Figure 2 shows the FTIR spectrum while Figure 3 shows the GC-MS chromatogram. The phytochemical compounds are presented in Table 2.

Table 1 Functional groups from the FTIR spectrum

S/No.	Peak (cm ⁻¹)	Functional group
1.	3405.1	(O-H) Hydrogen bonded alcohols, phenols
	3004.2	C – H (aromatic ring)
2.	2926.0, 2855.1	C-H (alkyl)

- **3** 1736, 1707, C=O, C=C 1517.0
- **4** 1267,3 C-C





Figure	2	the	FTIR	spectrum	of	Aframomum	melegueta
--------	---	-----	------	----------	----	-----------	-----------




Nigerian Journal of Chemical Research


Figure 3. The GC-MS microgram of Aframomum melegueta

Table 2 Compounds identified from the GC-MS analysis and their docking scores


S.n	Compound	Area	Pubchem	Structure	Molecul	Molec	Docki
0		peak	id		ar	ular	ng
					formula	weight	score
							(k cal
							mol -1)
1	Androstanolone	Control	10635		$C_{19}H_{30}O_2$	290.4	-11.1
				0 H	,		
2	Caryophyllene	0.1674	5281515	H	C15H24	204.35	-8.5
3	Humulene	0.4481	5281520	H	C15H24	204.35	-8.5
				H			
4	(3S,3aS,8aR)-	0.0910	73809332		$C_{15}H_{24}$	204.35	-7.7
	6,8a-Dimethyl-3-						
	(prop-1-en-2-yl)-						
	1,2,3,3a,4,5,8,8a-						
	octahydroazulene						

5	1,6,10-	0.0469	8888		C15H26O	222.37	-7.2
	Dodecatrien-3-ol,			н. о			
	3,7,11-trimethyl-						
6	4-Methyl-1,4- heptadiene	0.0543	5362810	H H	C ₈ H ₁₄	110.20	-5.1
7	2-Cyclopenten-1- one, 2-methyl-	0.0471	14266	•	C ₆ H ₈ O	96.13	-4.9
8.	Butan-2-one, 4-(3- hydroxy-2- methoxyphenyl)-	2.2364	586455	Р С С С С С С С С С С С С С С С С С С С	C11H14O3	194.23	-6.8
9.	Ar-tumerone	0.0454	558221	•	C ₁₅ H ₂₀ O	216.32	-8.4
10	1-Propanone, 1- cyclohexyl-	0.0466	70748		C9H16O	140.22	-5.9
11	Curlone	0.0334	196216	Ţ	C15H22O	218.33	-8.4





methoxyphenyl)d ecan-3-one 71391212 C₁₈H₂₈O₄ 308.4 24 1-(3,4-0.2926 -7.1 Dimethoxyphenyl)-5hydroxydecan-3one 14122970 $C_{21}H_{34}O_2$ 318.5 25 Methyl 0.0386 -7.0 8,11,14,17eicosatetraenoate $C_9H_{12}O_3$ 168.19 -5.9 26 Phenol, 2- 0.7151 79662 H²O methoxy-4-(methoxymethyl)-1-(4-Hydroxy-3-27 0.1080 C₁₉H₂₈O₃ 304.4 -8.0 6442560 methoxyphenyl)d odec-4-en-3-one



Absorption,distribution,metabolism,ADMETpropertieswerepredictedusingexcretion,and toxicity (ADMET)Resultsadmetsar software; the results are presented

in Table 3. The results showed that none of compounds violated more than one of Lipinski's rule of five ³⁰. Based on the

observed results all the studied compounds can be regarded as good drug lead candidates for the Sex hormone binding globulin.

Table 3 ADMET properties of some of the identified compounds with %>1

No.	Compound	MW	HIA	AOT	С	BBB	WS	AlogP	HBA	HBD	NRB
1.	Androstanolon e	290.45	+	1.996	-	+	-4.098	3.96	2	1	0
2.	Butan-2-one, 4-(3-hydroxy- 2-	194.23	+	2.052	-	-	0.676	1.92	3	1	4
3.	methoxypheny l)- 3-Decanone, l- (4-hydroxy-3- methoxypheny l)-	278.39	+	1.961	-	+	-3.872	4.26	3	1	10

4.	1-(4-Hydroxy-	276.38	+	2.26	-	+	-4.158	4.04	3	1	9
	3-										
	methoxypheny										
	l)dec-4-en-3-										
	one										
5.	Tyrosol,		+	1.711	-	+	-2.475	1.50	3	1	3
	acetate	180.20									
6.	1-(4-Hydroxy-	292.38	+	2.355	-	+	-3.715	3.44	4	1	10
	3-										
	methoxypheny										
	l)decane-3,5-										
	dione										
7.	5-Hydroxy-1-		+	1.864	-	-	-3.234	3.23	2	4	10
	(4-hydroxy-3-	294.4									
	methoxypheny										
	l)decan-3-one										

MW-Molecular weight, HBA-Number of hydrogen bond acceptor, HBD-Number of hydrogen bond donor, NRB-Number of rotatable bonds, C- Carcinogenicity,

Molecular docking Result

A total of 30 compounds obtained from the GC-MS analysis were docked with the sex hormone-binding globulin protein target using androstanolon as control for the molecular docking interaction to identify the compounds with good binding energies for the studied sex hormone-binding globulin (SHBG) receptor. Table 2 shows the binding scores for the 30 phytochemical compounds and the control while Table 4 show the binding scores, 3D and 2D interactions, forces of interaction and the amino acids involved in the molecular docking of


compounds with greater or equal to 2% in the GC-MS experiment. Low binding energy is an indication that a compound has good interaction with the protein target ³⁵. Of all the phytochemicals studied, 5-Hydroxy-1-(4hydroxy-3-methoxyphenyl)decan-3-one which was found to be present in 43.2511% of the sample, gave a binding energy of -7.0 Kcal mol⁻¹. It showed good interaction with the amino acids of the active site (asp 65 & Asn 82). It was found that the compound fitted perfectly into the binding pocket of the sex hormone-binding globulin. All the compounds studied had binding energies lower than -4.0 which is an indication of good interaction between the ligand and protein target.


Table 4: 3D and 2D protein-ligand interaction, amino acid of interaction and forces involvedin the molecular docking reactions

S/	Compound	Area	Doc	3D and 2D interactions	Amino	Interaction
no		peak	king		acids	forces
•			scor			
			e			

1 Androstanolone -11.1 Asp, 65, Conventional VAL A-11 LEU A:80 hydrogen bond, Asn 82, unfavorable Phe 67. Leu 80, donor-donor, Aky Di-Akyi Val 112 alkyl, pi-sigma, pi-alkyl 2 Butan-2-one, 4-2.236 -6.8 Asp Conventional 65,Phe 67, hydrogen bond, (3-hydroxy-2-4 methoxyphenyl)-ASP A:65 Leu 80. carbon n stage of His hydrogen bond, 81, Trp 66 pi-sigma, pialkyl 3 3-Decanone, 1-2.713 Ala 28, Conventional -4.5 Trp (4-hydroxy-3-1 170, hydrogen bond, methoxyphenyl)-Glu 176, carbon n silayi hydrogen bond, Leu 143, Leu 185 alkyl, pi-alkyl 4 1-(4-Hydroxy-3-14.22 Val 16. Conventional -5.0 methoxyphenyl) hydrogen bond. 35 Ala 28, dec-4-en-3-one Alkyl, pi-alkyl Leu 143, Leu, 185, Ser 187

Nigerian Journal of Chemical Research





CONCLUSION

Infertility is a problem that has affected many families today. In African, it is one of the main reasons for divorce. The present work investigates the role of *Aframomum melegueta* (Alligator pepper) in the inhibition

of sex hormone-binding globulin (SHBG) in relation to male infertility. FTIR and GC-MS examinations were performed on *Aframomum melegueta* powder to identify the functional groups and active components therein, Admet examination was used to screen the compounds for drug likeliness while molecular docking was performed to identify the ligand-target interactions between the compound and the sex hormonebinding target. The phytochemical screening revealed 30 compounds. The molecular docking result revealed good interactions between the ligands and target while ADMET study showed that the compounds above 1 % in the GC-MS study represents good drug-lead candidates for the sex hormone-binding globulin studied.

REFERENCES

- Legese, N., Tura, A. K., Roba, K. T. and Demeke, H., (2023). PLoS One, 10, (2023) 291912
- Labinjo, T., African Journal of Reproductive Health, 26, (2022) 49.
- Dyer, S. J., ESHRE Monographs, 2008, (2008) 48. https://doi.org/10.1093/humrep/de n157
- 4. Esther, M. J., Subramaniyan, V., Kumar, A. P, Subramanian, M. and Palani, M., harmacog J, 9 (2017)35.
- He, Z., Yin, G., Li, Q. Q., Zeng, Q. and Duan, J., PMID, 35(2021)2503. doi: 10.21873/invivo.12531. PMID:

34410936; PMCID: PMC8408700.

- 6. Huang, R., Chen, J., Guo, B. *et al.* Mol Med, 30(2024)11 https://doi.org/10.1186/s10020-023-00771-x
- Chen, P. C., Chen, Y.J., Yang, C. C., Lin, T. T., Huang, C. C., Chung, C. H., Sun, C. A. and Chien, W. C., World J Mens Health, 40(2022)490. https://doi.org/10.5534/wjmh.210 098.
- Guo, D., Li, S., Behr, B. and Eisenberg, M. L. World J Mens Health, 35(2017)59. doi: 10.5534/wjmh.2017.35.2.59. PMID: 28868816; PMCID: PMC5583372.
- Sansone, A., Di-Dato, C., De-Angelis, C., Menafra, D., Pozza, C., Pivonello, R., Isidori, A. and Gianfrilli, D., Reprod Biol Endocrinol.,15(2018)3. doi: 10.1186/s12958-018-0320-7. PMID: 29334961; PMCID: PMC5769315.
- 10. Harmed, M. A., Ekundina, V. O., and Akhigbe R. E., Reprod Bio Endocrinol, 21(2023) 69.
- 11. Alemany, M, Int J Mol Sci., 8(2022)11952. doi: 10.3390/ijms231911952. PMID: 36233256; PMCID: PMC9569951.
- 12. Elizabeth, A. P., Michael, F. L., Nader, R., Philip, W. K., Yen-Ching, C., Meir, J. S., Walter, C.

W. and Edward, G., Epidemiol Biomarkers Prev., 14(2005)1262.

- Schulster, M., Bernie, A. M. and Ramasamy, R., Asian J Androl., 18(2016)435. doi: 10.4103/1008-682X.173932. PMID: 26908066; PMCID: PMC4854098.
- 14. Hess, R. A., Reprod Biol Endocrinol, 1(2003)52. https://doi.org/10.1186/1477-7827-1-52.
- 15. Qu, X. and Donnelly R, Int J Mol Sci. 1(2020)8191. doi: 10.3390/ijms21218191. PMID: 33139661; PMCID: PMC7663738
- 16. Colin, S, Ann C/in Biochem 27(1990)532.
- 17. Cui, Y. M. A., Guo Y. M. D., Qiao S. M. A., Leng L. M. A., Xie Z. M. A., Chen H. M. D. and Wang X. M. D., Medicine (2017), 96(2017)e7753, | DOI: 10.1097/MD.00000000007753
- 18. Anne, S. V., Gerhard. P., South African Journal of Botany,133 (2020)54.
- 19. Zhang, J., Onakpoya, I. J., Posadzki, P. and Eddouks, M., Evid Based Complement Alternat Med. 2015(2015)316706. doi: 10.1155/2015/316706. Epub. PMID: 25838831; PMCID: PMC4370194
- 20. Kasole, R., Martin, H. D. and Kimiywe, J., evid Based complement alternat med, (2019) | Article ID 2835691 | https://doi.org/10.1155/2019/2835 691

- 21. Osuntokun, O. T., Annals of Microbiology and Infectious Diseases, 3(2020)1.
- 22. Bennett, V., Inengite, A. K., IOSR Journal of Applied Chemistry (IOSR-JAC), 15(2022)14.
- 23. Okaiyeto, K., Adeoye, R. I. and Oguntibeju, O. O., Journal of king Saudi University science, (2021)33.
- 24. Adefegha, S. A., Oboh, G., Adefegha, O. M. and Henle, T., Pathophysiology, 23(2016)191. <u>https://doi.org/10.1016/j.pathophy</u> <u>s.2016.05.005</u>.
- 25. Doherty, V. F., Olaniran, O. O., Kanife, U. C., International Journal of Biology 2(2010)(2)
- 26. Mawire, P., Mozirandi, W., Heydenreich, M., Chi, G. F. and Mukanganyama, S., Hindawi Advances in Pharmacological and Pharmaceutical Sciences, (2021)18 Article ID 8842629, https://doi.org/10.1155/2021/8842 629
- 27. Chaudhari, M. K., Chaudhari, R. D., Girase, P. R., Suryawanshi, H. P., and Pawar, S. P., Research J. Pharm. and Tech.; 11(2018)5373. doi: 10.5958/0974-360X.2018.00979.4
- 28. Duru, C. E., Duru, I. A., and Adegboyega, A., Bulletin of the National research Centre, , 45(2021)2. <u>https://doi.org/10.1186/s42269-021-00517-x</u>

- 29. Morvin, Y. J. E., Vijayakumar, S., Arulmozhi, P. K., Mahadevan, S., Manogar, P., Pharmacogn J., 9(2017) s35.
- 30. Lipinski CA. Rule of five in 2015 and beyond: Target and ligand structural limitations, ligand chemistry structure and drug discovery project decisions, Advance Drug Delivery Rev. 2016;2015(101):34–41.
- Jahangeer, M., Mustafa, G., Munir, N., Ahmed, S. and Al-Anazi, K. M., Molecules 28(2023)7693. https://doi.org/10.3390/ molecules28237693
- Teow, C. T., Ismail, S. and Jung, M. T., Tropical Journal of Pharmaceutical Research March; 13(2014)339.
- 33. Spyrakis, F., Amadasi, A., Fornabaio, M., Abraham, D. J. and Mozzarelli, A., European Journal of Medicinal Chemistry, , 42(2007)921. DOI: 10.1016/j.ejmech.2006.12.037
- 34. Riaz, M., Khalid, R., Afzal, M., Anjum, F., Fatima, H., Zia, S., Rasool, G., Egbuna, C., Mtewa, A. G., Uche, C. Z. and Aslam, M. A., Food Sci Nutr. 17(2023)2500. doi: 10.1002/fsn3.3308. PMID: 37324906; PMCID: PMC10261751.
- 35. Adinortey, C. A., Kwarko, G. B., Koranteng, R., Boison, D., Obuaba, I., Wilson, M. D., Kwofie, S. K., Curr Issues Mol Biol., 21 (2022)963. doi:

10.3390/cimb44020064. PMID: 35723349; PMCID: PMC8928985.